Fixing the broken patent system: From Marrakech and back again
Marrakech was home to the signing of the TRIPS Agreement in 1995, an agreement that has been exploited by pharmaceutical...
Storify: Pathways to Access #GSIPA2M
[View the story “Pathways to Access! #GSIPA2M (15-17 Jan 2018)” on Storify] SaveSave
GSIPA2M: Malaysia Ministry of Health 2018 winner of the Leadership Award on Intellectual Property and Access to Medicines
Malaysia’s “historic decision” to issue a compulsory license on Hep C medicine, sofosbuvir, stands up to Big Pharma, and will mean...
Argentina: Patent rejected on hepatitis C drug, sofosbuvir
A decision by the patent office in Argentina (INPI) to reject Gilead’s patent on key hepatitis C drug, sofosbuvir, is...
São Paulo protest exposes how Gilead’s actions block access to medicines around the world
In São Paulo, on 31 October 2017, activists from around the world held a protest at the headquarters of...
The Indonesian patent club – and its impact on Hep C treatment
Communities are refusing to accept patent abuse – challenging unmerited patents, and finding ways around them in the meantime. Community...
Myanmar: Creating an intellectual property law that protects public health
Lobbying for an intellectual property law that doesn’t just serve big business, but protects public health and encourages innovation in...